查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1863484

抗發炎治療藥物市場依治療類別、作用機制、給藥途徑、通路、適應症和最終用戶分類－2025年至2032年全球預測

Anti-Inflammatory Therapeutics Market by Therapeutic Class, Mechanism Of Action, Route Of Administration, Distribution Channel, Indication, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，抗發炎治療市場將成長至 1,596.9 億美元，複合年成長率為 5.52%。

關鍵市場統計數據
基準年 2024 1038.5億美元
預計年份：2025年 1094.9億美元
預測年份 2032 1596.9億美元
複合年成長率 (%) 5.52%

整合臨床獎勵、相關人員激勵和策略重點，為決策者建構現代抗發炎治療格局

發炎性疾病治療領域呈現出快速的科學進步、不斷變化的臨床範式和日益複雜的商業性環境。分子生物學和免疫學的進步拓展了臨床醫生可用的治療手段，而患者的期望和支付方日益嚴格的審查則凸顯了藥物安全性、長期療效和真實世界療效的重要性。本文概述了當前的治療環境，並綜合獎勵了共同影響藥物研發和商業化進程的臨床促進因素、監管影響和相關人員。

轉化醫學的突破性進展正在為多種治療模式創造機遇，涵蓋從靶向細胞激素抑製劑到調節細胞內訊號傳導的口服小分子藥物等。然而，傳統抗發炎藥物仍然是控制急性症狀和手術全期管理的核心，凸顯了整合式醫療模式的必要性。本節結合臨床觀點和市場導向的視角，為後續分析奠定基礎，重點在於闡述治療方法差異化、劑型和分銷策略如何影響藥物的接受度和生命週期規劃。

本執行摘要旨在提供平衡且基於證據的敘述，以支持策略優先排序。它重點闡述了治療創新與未滿足的臨床需求相契合的領域、治療模式轉變將如何影響相關人員的行為，以及應指導投資決策的專案考量。簡而言之，本導言旨在引導讀者了解影響抗發炎領域治療藥物開發和取得的關鍵因素。

對科學突破、適應性監管途徑和商業性壓力進行綜合觀點，正在從根本上改變治療創新和獲取途徑的動態。

抗發炎領域的蓬勃發展得益於科學、監管和商業性三方面關鍵轉折點的匯聚，這些轉折點正在重塑治療方法的發現、開發和應用方式。近年來，治療策略顯著從廣泛的免疫抑制轉向靶向調節特定的發炎通路，這重新定義了人們對療效、安全性和長期疾病控制的預期。同時，監管路徑也不斷發展，以適應新的治療方式和適應性開發策略，迫使申辦方在計畫設計早期就納入監管策略。

在商業方面，支付方和醫療系統正利用真實世界數據 (RWE) 和基於價值的合約來尋找能夠展現持續療效和成本效益的治療方案。這種壓力促使生產商將試驗終點與以患者為中心的療效和衛生經濟學指標更加緊密地結合。此外，藥物傳遞技術和遠端醫療的創新正在拓展用藥途徑，催生新的分銷策略和以患者為中心的支援服務，從而影響患者的依從性和留存率。

這些累積效應正在建構一個更為複雜但也充滿機會的生態系統，其中治療方法差異化呈現多維度特徵。科學進步使得疾病生物學標靶化成為可能，監管調整促進了創新研發框架的形成，而商業性相關人員也日益重視可驗證的價值。因此，能夠整合臨床證據產生、與支付方合作以及靈活商業化計畫的機構，將更有利於駕馭不斷變化的市場環境。

深入分析2025年美國關稅調整對整個治療產品組合的供應鏈韌性、生產策略和產品供應的影響

關稅政策和貿易趨勢會對醫藥原料和成品的供應和成本結構產生微妙而顯著的影響。 2025年美國關稅調整為供應鏈規劃、籌資策略和國際採購決策引入了新的變數。製造商和經銷商正在重新評估供應商所在地，尋找替代製造地，並審查庫存政策，以維持供應的連續性並保護其利潤率結構。

這些調整對注射劑和生物製藥行業尤其重要，因為這些行業的低溫運輸物流和契約製造關係與生產計劃緊密相關。一些公司加快了垂直整合和產能投資，以降低跨國成本波動帶來的風險。同時，隨著越來越多的企業尋求降低地緣政治風險並縮短關鍵療法的前置作業時間，近岸外包和區域製造地也日益受到重視。

除了生產環節，支付者和醫療系統也可能受到間接影響，因為它們需要調整採購慣例以適應成本結構的變化。醫療服務提供者正在修訂藥品目錄和集團採購協議，以在確保臨床適用性的同時維持價格可負擔性。總而言之，這種情況凸顯了建立具有韌性的供應鏈、基於情境的財務模型以及與相關人員積極溝通的重要性，以維持產品供應並確保患者獲得治療。

透過對治療領域、作用機制、給藥途徑、分銷管道、適應症和終端用戶趨勢進行全面細分分析，深入了解與實際開發和商業化挑戰相關的因素。

從精細的市場區隔觀點來看，不同治療領域、作用機制、給藥途徑、分銷管道、適應症和終端用戶都面臨著不同的策略挑戰，這些挑戰各自為產品開發和商業化帶來了獨特的機會和限制。按治療領域分類，市場涵蓋了緩解疾病抗風濕藥（DMARDs）、 Janus激酶抑製劑、非類固醇消炎劑（NSAIDs）和磷酸二酯酶抑制劑（PDE抑制劑），此外還包括生物製藥和糖皮質激素，每種藥物對臨床證據、生產複雜性和上市後安全性監測的要求各不相同。在作用機轉分類方面，治療方法標靶Cyclooxygenase路徑、白細胞介素訊號連鎖、 Janus激酶級聯反應、磷酸二酯酶、腫瘤壞死因子等。這種多樣化的作用機制需要個人化的生物標記策略和差異化的臨床終點。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 整合生物製藥遞送平台以增強標靶發炎消退
  • 針對發炎小體介導的疾病路徑的新型小分子抑制劑的出現
  • 利用人工智慧對患者進行分層，引入個人化抗發炎療法
  • 開發口服胜肽製劑以提高慢性發炎疾病患者的用藥依從性
  • 增加對基於微生物組的腸道發炎管理干預策略的投資
  • 用於增強抗炎化合物皮膚滲透性的擴展型局部奈米載體系統
  • 監管簡審類加快了治療發炎性疾病（存在高度未滿足需求）藥物的核准流程

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：依治療類別分類的抗發炎藥市場

  • 生物製藥
  • 皮質類固醇
  • 緩解疾病抗風濕藥物
  • Janus激酶抑制劑
  • 非類固醇消炎劑
  • 磷酸二酯酶抑制劑

9. 按作用機轉分類的抗發炎治療藥物市場

  • Cyclooxygenase抑制劑
  • 白細胞介素抑制劑
  • Janus激酶抑制劑
  • 磷酸二酯酶抑制劑
  • 腫瘤壞死因子抑制劑

第10章 按給藥途徑分類的抗發炎治療藥物市場

  • 口服
  • 腸外
    • 肌肉內注射
    • 靜脈注射
    • 皮下注射
  • 外用藥物
    • 奶油
    • 凝膠
    • 軟膏

第11章 按分銷管道分類的抗發炎治療藥物市場

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章：按適應症分類的抗發炎治療藥物市場

  • 氣喘和肺部疾病
  • 痛風
  • 發炎性腸道疾病
    • 克隆氏症
    • 潰瘍性大腸炎
  • 骨關節炎
  • 銀屑病
  • 類風濕性關節炎

第13章 按最終用戶分類的抗發炎治療市場

  • 診所
  • 居家照護
  • 醫院
  • 專業醫療機構

第14章 各地區抗發炎治療藥物市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 抗發炎治療藥物市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：各國抗發炎治療藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • AbbVie Inc.
    • Johnson & Johnson
    • Amgen Inc.
    • Novartis AG
    • Pfizer Inc.
    • F. Hoffmann-La Roche Ltd
    • Merck & Co., Inc.
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • Sanofi SA
Product Code: MRR-5C6F41F5B03B

The Anti-Inflammatory Therapeutics Market is projected to grow by USD 159.69 billion at a CAGR of 5.52% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 103.85 billion
Estimated Year [2025] USD 109.49 billion
Forecast Year [2032] USD 159.69 billion
CAGR (%) 5.52%

Framing the contemporary anti-inflammatory therapeutics landscape by synthesizing clinical innovation, stakeholder incentives, and strategic priorities for decision-makers

The therapeutic landscape for inflammatory disorders is characterized by rapid scientific progress, shifting clinical paradigms, and intensifying commercial complexity. Advances in molecular biology and immunology have expanded the toolbox available to clinicians, while patient expectations and payer scrutiny have elevated the importance of comparative safety, long-term outcomes, and real-world effectiveness. This introduction frames the current environment by synthesizing clinical drivers, regulatory influences, and stakeholder incentives that collectively shape development and commercialization pathways.

Translational breakthroughs have created opportunities across a spectrum of modalities, from targeted cytokine inhibitors to orally administered small molecules that modulate intracellular signaling. At the same time, traditional anti-inflammatory agents remain central to acute symptom control and perioperative management, reinforcing the need for integrated care models. By combining clinical insight with market-oriented perspectives, this section sets the groundwork for subsequent analysis, clarifying how therapeutic differentiation, delivery format, and distribution strategy influence adoption and lifecycle planning.

The objective of this executive summary is to present a balanced, evidence-informed narrative that supports strategic prioritization. It emphasizes where therapeutic innovation aligns with unmet clinical need, how shifting treatment paradigms affect stakeholder behavior, and what programmatic considerations should guide investment decisions. In short, the introduction is intended to orient readers to the principal forces shaping therapeutic development and access in the anti-inflammatory domain.

An integrated view of scientific breakthroughs, adaptive regulatory pathways, and commercial pressures that are fundamentally altering treatment innovation and access dynamics

Momentum in the anti-inflammatory space is driven by convergent scientific, regulatory, and commercial inflection points that are reshaping how therapies are discovered, developed, and adopted. Recent years have seen a pronounced pivot from broad immunosuppression toward targeted modulation of discrete inflammatory pathways, which has recalibrated expectations for efficacy, safety, and long-term disease control. Concurrently, regulatory pathways have evolved to accommodate novel modalities and adaptive development approaches, prompting sponsors to embed regulatory strategy early in program design.

Commercially, payers and health systems are leveraging real-world evidence and value-based contracting to distinguish treatments that demonstrate durable benefit and cost offsets. This pressure has encouraged manufacturers to align trial endpoints more closely with patient-centered outcomes and health economic measures. Additionally, technological innovations in drug delivery and telemedicine have broadened access pathways, enabling novel channel strategies and patient-centric support services that can influence adherence and persistence.

The cumulative effect is a more complex but opportunity-rich ecosystem in which therapeutic differentiation is multi-dimensional. Scientific advances permit more precise targeting of disease biology, regulatory adaptations encourage innovative development frameworks, and commercial stakeholders increasingly demand demonstrable value. As a result, organizations that integrate clinical evidence generation, payer engagement, and agile commercialization planning will be best positioned to navigate the evolving terrain.

A nuanced analysis of how 2025 United States tariff adjustments are influencing supply chain resilience, manufacturing strategy, and product availability across therapeutic portfolios

Tariff policies and trade dynamics can exert a subtle yet material influence on the availability and cost structure of pharmaceutical inputs and finished products. Changes to United States tariffs in 2025 have introduced new variables for supply chain planning, procurement strategy, and international sourcing decisions. Manufacturers and distributors have responded by reassessing supplier footprints, qualifying alternate manufacturing sites, and re-evaluating inventory policies to maintain continuity of supply and to protect margin structures.

These adjustments have been particularly relevant for parenteral products and biologics, where cold-chain logistics and contract manufacturing relationships are tightly integrated with production timelines. In some instances, firms have accelerated vertical integration or capacity investments to mitigate exposure to cross-border cost fluctuations. Concurrently, emphasis on nearshoring and regional manufacturing hubs has increased, as organizations seek to reduce geopolitical risk and to shorten lead times for critical therapeutic agents.

Beyond manufacturing, payers and health systems may see indirect effects as procurement practices adapt to changed cost bases. Providers are reassessing formularies and group purchasing arrangements to preserve affordability while ensuring clinical adequacy. Overall, the tariff landscape underscores the importance of resilient supply chains, scenario-based financial modeling, and proactive stakeholder communication to sustain product availability and to preserve patient access.

Comprehensive segmentation-driven insights that map therapeutic class, mechanism, delivery, channels, indications, and end-user dynamics to practical development and commercialization imperatives

A granular segmentation lens reveals distinct strategic imperatives across therapeutic class, mechanism of action, route of administration, distribution channel, indication, and end user, each presenting unique opportunities and constraints for product development and commercialization. Based on Therapeutic Class, the market spans Biologics and Corticosteroids as well as Disease Modifying Antirheumatic Drugs, Janus Kinase Inhibitors, Nonsteroidal Anti-Inflammatory Drugs, and Phosphodiesterase Inhibitors, with each class posing different demands for clinical evidence, manufacturing complexity, and post-marketing safety surveillance. Based on Mechanism Of Action, therapies target Cyclooxygenase pathways, Interleukin signaling, Janus Kinase cascades, Phosphodiesterase enzymes, and Tumor Necrosis Factor, and the mechanistic diversity necessitates tailored biomarker strategies and differentiated clinical endpoints.

Based on Route Of Administration, therapeutic delivery choices include Oral, Parenteral, and Topical formats, where parenteral administration divides further into Intramuscular, Intravenous, and Subcutaneous approaches and topical treatments are delivered via Creams, Gels, and Ointments; these delivery distinctions influence adherence profiles, healthcare utilization patterns, and the complexity of manufacturing and distribution. Based on Distribution Channel, therapies move through Hospital Pharmacy networks, Online Pharmacy platforms, and Retail Pharmacy outlets, and each channel carries different requirements for cold-chain, patient support, and reimbursement interactions. Based on Indication, clinical targets include Asthma And Pulmonary Diseases, Gout, Inflammatory Bowel Disease, Osteoarthritis, Psoriasis, and Rheumatoid Arthritis, with Inflammatory Bowel Disease further categorized into Crohn's Disease and Ulcerative Colitis; indication-specific natural history affects trial design, responder definitions, and long-term safety monitoring. Based on End User, settings span Clinic, Home Care, Hospital, and Specialty Center, with each care environment influencing point-of-care delivery, patient education needs, and support service integration.

Taken together, this segmentation framework highlights that therapeutic success is contingent on aligning molecule attributes with the operational realities of manufacturing, channels, and clinical care settings. Strategic planners should consider how a therapy's class and mechanism guide evidence generation, how administration route shapes patient experience and adherence, and how distribution and end-user dynamics will affect access, uptake, and lifecycle management. In practice, cross-functional alignment between R&D, commercial, manufacturing, and market access teams is essential to translate segment-specific requirements into executable development and launch plans.

Region-specific strategic considerations that reconcile regulatory diversity, reimbursement paradigms, and infrastructure realities across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics exert a strong influence on regulatory interactions, reimbursement pathways, and commercial execution, with each geography presenting distinctive clinical paradigms and operational priorities. In the Americas, healthcare systems vary from highly privatized to public payer-dominated models, driving heterogeneity in formulary decisions, access timelines, and patient support program requirements. Clinical practice patterns and guideline adoption in this region influence comparative effectiveness expectations and the evidence standards that payers and providers demand.

In Europe, Middle East & Africa, regulatory harmonization efforts coexist with significant variation in reimbursement capacity and health technology assessment methodologies. Manufacturers must navigate diverse pricing environments, local guideline adoption, and varying degrees of infrastructure for specialty care, which affects launch sequencing and patient access strategies. Capacity constraints in certain markets can also influence distribution and cold-chain investments.

In Asia-Pacific, rapid adoption of innovative therapies is often balanced against affordability pressures and evolving regulatory frameworks that can accelerate approval for therapies addressing high unmet need. Local manufacturing partnerships and regional clinical development programs are frequently used to support access and meet regulatory expectations. Across all regions, cross-border supply chain resilience, pharmacovigilance harmonization, and culturally tailored patient support models are critical for ensuring sustainable access and maximizing clinical impact.

How leading firms are combining scientific differentiation, strategic partnerships, and lifecycle tactics to optimize therapeutic pipelines and demonstrate payer-aligned value

Competitive behavior among leading companies reflects a mix of scientific differentiation, strategic partnerships, and portfolio optimization. Industry players are prioritizing targeted therapies with clear mechanistic rationales and have been investing in biologics and small molecules that offer improved safety and specificity compared with older broad-spectrum agents. Cross-sector collaborations and licensing arrangements are widespread as firms seek to complement internal capabilities with external innovation, accelerate time to clinic, and de-risk late-stage development.

Manufacturers are also placing an increased emphasis on life-cycle management tactics, including reformulations, novel delivery systems, and indication expansion strategies to extend therapeutic relevance. In parallel, companies are investing in real-world evidence generation, patient engagement platforms, and outcomes-based contracting models to demonstrate value to payers and health systems. Organizationally, there is a trend toward integrated teams that combine clinical development, market access, and commercial functions to ensure that evidence packages align with payer expectations and provider needs.

These competitive dynamics underscore the importance of agility, data-driven decision-making, and strategic partnering. Enterprises that can efficiently translate mechanistic insight into differentiated products, while simultaneously building robust evidence generation and access strategies, are positioned to navigate both clinical and commercial complexities.

Practical and prioritized actions for executives to align R&D, manufacturing, market access, and commercial teams to ensure resilient launches and sustained therapeutic adoption

Industry leaders should adopt an integrated approach that aligns early-stage scientific choices with downstream access and commercial requirements. Initiatives should include embedding payer and health economics input at the earliest program design stages to ensure that trial endpoints and health outcome measures will be credible to reimbursement stakeholders. Simultaneously, investments in manufacturing flexibility and geographic diversification will safeguard supply continuity and reduce exposure to trade disruptions.

Commercial plans must prioritize patient-centric delivery models and digital support mechanisms that improve adherence and enable remote monitoring of therapeutic response. Strategic partnerships with clinical networks, specialty pharmacies, and technology vendors can accelerate patient access and reduce the burden on traditional distribution channels. Moreover, life-cycle management should be treated as a continuous process that encompasses reformulation, delivery innovation, and indication sequencing to sustain clinical relevance.

Finally, organizations should institutionalize agile governance frameworks that facilitate cross-functional decision-making, rapid evidence integration, and scenario-based planning. These practical steps will enable companies to translate clinical innovation into durable commercial success while maintaining alignment with payer expectations and patient needs.

Transparent methodology combining expert interviews, targeted secondary review, and cross-sectional analytic techniques to validate clinical, regulatory, and operational insights

The research underpinning this executive summary synthesizes primary qualitative interviews, targeted secondary literature review, and structured analysis of regulatory and policy changes. Key informant interviews included clinical thought leaders, supply chain executives, market access specialists, and therapeutic area experts to capture multi-stakeholder perspectives. Secondary sources encompassed peer-reviewed clinical literature, regulatory guidance documents, and technical white papers that contextualize mechanism-specific evidence and delivery considerations.

Analytical methods combined thematic synthesis with cross-sectional mapping of segmentation attributes to identify where clinical innovation intersects with operational constraints. Evidence validation steps included triangulation of interview findings with published clinical data and supply chain disclosures. Limitations and uncertainties are acknowledged, and sensitivity to evolving regulatory and trade dynamics was incorporated through scenario-based analysis. The methodology emphasizes transparency in source attribution and reproducibility of analytic choices to support informed decision-making.

Conclusion synthesizing how therapeutic innovation, evidence alignment, and operational execution collectively determine long-term success and patient impact in inflammatory diseases

In summary, the anti-inflammatory therapeutics landscape is being reshaped by precise mechanistic targeting, adaptive regulatory expectations, and heightened demands for demonstrable real-world value. These forces create both opportunities and responsibilities for developers, payers, and providers to collaborate on evidence generation, supply chain resilience, and patient-centered care models. Therapeutic differentiation increasingly requires alignment across molecule design, delivery format, and market access strategies to ensure uptake and sustainable patient benefit.

Moving forward, stakeholders who integrate clinical evidence with pragmatic operational planning will be best positioned to deliver meaningful outcomes while navigating commercial complexity. Sustained success depends not only on scientific innovation but also on the ability to orchestrate manufacturing, regulatory, and payer engagements in a coordinated fashion. The conclusion reinforces that strategic foresight, cross-functional execution, and a relentless focus on patient outcomes are the foundational elements for enduring impact in the anti-inflammatory domain.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of biologic drug delivery platforms to enhance targeted inflammation resolution
  • 5.2. Emergence of novel small molecule inhibitors addressing inflammasome-mediated disease pathways
  • 5.3. Adoption of artificial intelligence in patient stratification for personalized anti-inflammatory therapy
  • 5.4. Development of oral peptide formulations improving compliance in chronic inflammatory conditions
  • 5.5. Rising investment in microbiome-based interventions for gut inflammation management strategies
  • 5.6. Expansion of topical nanocarrier systems to increase skin permeation of anti-inflammatory compounds
  • 5.7. Regulatory fast track designations accelerating approval timelines for high unmet need inflammatory drugs

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Anti-Inflammatory Therapeutics Market, by Therapeutic Class

  • 8.1. Biologics
  • 8.2. Corticosteroids
  • 8.3. Disease Modifying Antirheumatic Drugs
  • 8.4. Janus Kinase Inhibitors
  • 8.5. Nonsteroidal Anti-Inflammatory Drugs
  • 8.6. Phosphodiesterase Inhibitors

9. Anti-Inflammatory Therapeutics Market, by Mechanism Of Action

  • 9.1. Cyclooxygenase Inhibitors
  • 9.2. Interleukin Inhibitors
  • 9.3. Janus Kinase Inhibitors
  • 9.4. Phosphodiesterase Inhibitors
  • 9.5. Tumor Necrosis Factor Inhibitors

10. Anti-Inflammatory Therapeutics Market, by Route Of Administration

  • 10.1. Oral
  • 10.2. Parenteral
    • 10.2.1. Intramuscular
    • 10.2.2. Intravenous
    • 10.2.3. Subcutaneous
  • 10.3. Topical
    • 10.3.1. Creams
    • 10.3.2. Gels
    • 10.3.3. Ointments

11. Anti-Inflammatory Therapeutics Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Anti-Inflammatory Therapeutics Market, by Indication

  • 12.1. Asthma And Pulmonary Diseases
  • 12.2. Gout
  • 12.3. Inflammatory Bowel Disease
    • 12.3.1. Crohn's Disease
    • 12.3.2. Ulcerative Colitis
  • 12.4. Osteoarthritis
  • 12.5. Psoriasis
  • 12.6. Rheumatoid Arthritis

13. Anti-Inflammatory Therapeutics Market, by End User

  • 13.1. Clinic
  • 13.2. Home Care
  • 13.3. Hospital
  • 13.4. Specialty Center

14. Anti-Inflammatory Therapeutics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Anti-Inflammatory Therapeutics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Anti-Inflammatory Therapeutics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. AbbVie Inc.
    • 17.3.2. Johnson & Johnson
    • 17.3.3. Amgen Inc.
    • 17.3.4. Novartis AG
    • 17.3.5. Pfizer Inc.
    • 17.3.6. F. Hoffmann-La Roche Ltd
    • 17.3.7. Merck & Co., Inc.
    • 17.3.8. Bristol-Myers Squibb Company
    • 17.3.9. Eli Lilly and Company
    • 17.3.10. Sanofi S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. ANTI-INFLAMMATORY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. ANTI-INFLAMMATORY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANTI-INFLAMMATORY THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISEASE MODIFYING ANTIRHEUMATIC DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISEASE MODIFYING ANTIRHEUMATIC DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISEASE MODIFYING ANTIRHEUMATIC DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISEASE MODIFYING ANTIRHEUMATIC DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISEASE MODIFYING ANTIRHEUMATIC DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISEASE MODIFYING ANTIRHEUMATIC DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY JANUS KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY JANUS KINASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY JANUS KINASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY JANUS KINASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY JANUS KINASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY JANUS KINASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CYCLOOXYGENASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CYCLOOXYGENASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CYCLOOXYGENASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CYCLOOXYGENASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CYCLOOXYGENASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CYCLOOXYGENASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY JANUS KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY JANUS KINASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY JANUS KINASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY JANUS KINASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY JANUS KINASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY JANUS KINASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CREAMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CREAMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CREAMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CREAMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CREAMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CREAMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY GELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY GELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY GELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY GELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY GELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY GELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY OINTMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY OINTMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY OINTMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ASTHMA AND PULMONARY DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ASTHMA AND PULMONARY DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ASTHMA AND PULMONARY DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ASTHMA AND PULMONARY DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ASTHMA AND PULMONARY DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ASTHMA AND PULMONARY DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY GOUT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY GOUT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY GOUT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY GOUT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY GOUT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY GOUT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CROHN'S DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CROHN'S DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CROHN'S DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CROHN'S DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ULCERATIVE COLITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ULCERATIVE COLITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ULCERATIVE COLITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ULCERATIVE COLITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY OSTEOARTHRITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY OSTEOARTHRITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY OSTEOARTHRITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY OSTEOARTHRITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PSORIASIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PSORIASIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PSORIASIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PSORIASIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PSORIASIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PSORIASIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CLINIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CLINIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CLINIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CLINIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CLINIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY SPECIALTY CENTER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY SPECIALTY CENTER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY SPECIALTY CENTER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY SPECIALTY CENTER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY SPECIALTY CENTER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY SPECIALTY CENTER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 258. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 260. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 264. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 270. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 278. LATIN AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 280. LATIN AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 282. LATIN AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 284. LATIN AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 285. LATIN AMERICA ANTI-INFLAMMATORY TH